For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Attruby represents a true breakthrough . These novel therapies preserve the transthyretin protein, halting its damaging build-up and lessening the burden of the illness. Indiv